Closing the Diabetic Loop Before we get into this week’s sector roundup, let’s talk about diabetes. I am a sucker for sweets, so much so… Read More »The Millennial sweet tooth (Sector Roundup: Week 10)
A Pain in the Behind I don’t fear a lot of things. Well, other than spiders, heights, and being stabbed. However, more than anything I… Read More »Putting colonoscopies behind us (Sector Roundup: Week 8)
Old Memories I have always been a sucker for nostalgia. When I first started writing for Equity Guru, I spent most of my time covering… Read More »A Trip Down Memory Lane (Sector Roundup: Week 2)
BioVaxys Technology (BIOV.C) announced today that Immunologist Yvelise Barrios, MD, PhD, has joined the Company as a Scientific Adviser to support development of CoviDTH. Furthermore,… Read More »BioVaxys Technology (BIOV.C) Affirms CoviDTH Diagnostic Approach is Safe and Effective in Humans
BioVaxys Technology (BIOV.C) announced today that the US Food and Drug Administration (FDA) has provided its official Written Response to the Company’s request for a… Read More »BioVaxys Technology (BIOV.C) Receives FDA Guidance, Begins Preparation of IND for Phase I/II Clinical Trials of CoviDTH
BioVaxys Technology (BIOV.C) announced today that the US Food and Drug Administration (FDA) has reviewed its pre-IND request for a Type B review of the… Read More »BioVaxys Technology (BIOV.C) Receives Positive FDA Response
BioVaxys Technology (BIOV.C) announced today that it that it has initiated the clinical trials for Covid-T, the company’s diagnostic platform for detecting T-cell activity, according… Read More »BioVaxys Technology (BIOV.C) gets the FDA nod to file for a Emergency Use Authorization for COVID-T
